Table 2.

Meta-analyses of perioperative chemotherapy phase III trials for MIBC

Study	Treatment type	Year	Number of trials	Patients	Therapy	OS (HR)	DFS (HR)
Tjokrowidjaja et al. [16]	Neoadjuvant + Adjuvant	2013	21	3986	Only abstract available	0.86	0.77
						(0.79 – 0.93)	(0.71 – 0.84)
Tjokrowidjaja et al. [16]	Neoadjuvant	2013	12	3047	Only abstract available	0.89	0.80
						(0.81 – 0.98)	(0.73 – 0.88)
Advanced bladder cancer- Meta-analysis Corporation [17]	Neoadjuvant	2005	11	3005	Platinum-based	0.86	0.78
						(0.77 – 0.95)	(0.77 –0.95)
Winquist et al. [18]	Neoadjuvant	2004	11^	2605	Cisplatin-based	0.90	Insufficient data for analysis+
						(0.82 – 0.99)
Tjokrowidjaja et al. [16]	Adjuvant	2013	9	939	Only abstract available	0.75	0.77
						(0.63 – 0.90)	(0.71 – 0.84)
Leow et al. [19] (Update of the meta-analysis below)	Adjuvant	2013	9#	945	Cisplatin-based	0.77	0.66
						(0.59 – 0.99)	(0.45 – 0.91)
Advanced bladder cancer meta-analysis corporation [20]	Adjuvant	2005	6*	491	Cisplatin-based	0.75	0.68
						(0.60 – 0.96)	(0.53 – 0.89)

OS: Overall Survival. DFS: Disease Free Survival. HR: Hazard Ratio.

^{^}11 trials had HR data for OS and only 8 trials had HR data for DFS.

⁺Less than half the number of patients assessed were available for DFS results, and therefore, no statistical pooling analysis was undertaken.

^#9 trials had HR data for OS and only 7 trials had HR data for DFS.

*6 trials had HR data for OS and only 5 trials had HR data for DFS.